Therapeutic vaccine for chronic diseases after the COVID-19 Era

9Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There is currently a respiratory disease outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After rapid development, RNA vaccines and adenoviral vector vaccines were approved within a year, which has demonstrated the strong impact of preventing infectious diseases using gene therapy technology. Furthermore, intensive immunological analysis has been performed to evaluate the efficiency and safety of these vaccines, potentially allowing for rapid progress in vaccine technology. After the coronavirus disease 2019 (COVID-19) era, the novel vaccine technology developed will expand to other vaccines. We have been developing vaccines for chronic diseases, such as hypertension, for >10 years. Regarding the development of vaccines against self-antigens (i.e., angiotensin II), the vaccine should efficiently induce a blocking antibody response against the self-antigen without activating cytotoxic T cells. Therefore, the epitope vaccine approach has been proposed to induce antibody production in response to a combination of a B cell epitope and exogenous T cell epitopes through major histocompatibility complex molecules. When these vaccines are established as therapeutic options for hypertension, their administration regimen, which might be a few times per year, will replace daily medication use. Thus, therapeutic vaccines for hypertension may be a novel option to control the progression of cerebrovascular diseases. Hopefully, the accumulation of immunological findings and vaccine technology advances due to COVID-19 will provide a novel concept for vaccines for chronic diseases.

Author supplied keywords

References Powered by Scopus

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

10860Citations
N/AReaders
Get full text

An mRNA vaccine against SARS-COV-2 — Preliminary report

2480Citations
N/AReaders
Get full text

Follicular Helper CD4 T cells (T <inf>FH</inf>)

2294Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges

19Citations
N/AReaders
Get full text

Latest hypertension research to inform clinical practice in Asia

19Citations
N/AReaders
Get full text

Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Nakagami, H., Hayashi, H., Shimamura, M., Rakugi, H., & Morishita, R. (2021, September 1). Therapeutic vaccine for chronic diseases after the COVID-19 Era. Hypertension Research. Springer Nature. https://doi.org/10.1038/s41440-021-00677-3

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

50%

Researcher 9

35%

Lecturer / Post doc 3

12%

Professor / Associate Prof. 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

42%

Biochemistry, Genetics and Molecular Bi... 7

29%

Nursing and Health Professions 4

17%

Pharmacology, Toxicology and Pharmaceut... 3

13%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 10

Save time finding and organizing research with Mendeley

Sign up for free